Remove 2025 Remove Clinical Development Remove Therapies
article thumbnail

Actithera draws new investors to radiopharma drug pitch

BioPharma Drive: Drug Pricing

Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. billion in 2025, giving the industry a glimpse of radiopharmaceuticals’ sales potential. subsidiary EMD Serono Inc.,

Drugs 131
article thumbnail

Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Covalent Modifiers

Neumller Cancer Discov (2025) 15 (1): 119138. The preclinical efficacy of zongertinib translates in objective responses in patients with HER2-dependent tumors, including cholangiocarcinoma (SDC4NRG1 fusion) and breast cancer (V777L HER2 mutation), thus supporting the ongoing clinical development of zongertinib.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

J&J’s Dual-Target CAR T-Cell Therapy Shows Promise in Large B-Cell Lymphoma

The Pharma Data

The data were presented during the 2025 European Hematology Association (EHA) Congress (Abstract #S239). Standard single-target CD19-directed CAR T-cell therapies typically enable long-term remissions in roughly 40% of patients, emphasizing a significant unmet need for new and more effective treatment strategies.

article thumbnail

Good things come in 3s

SugarCone Biotech

They have interesting patterns of expression in different cancer indications; thus, diverse therapies for attacking these targets have been developed. Each target and each therapeutic modality induce varying degrees of clinical efficacy, as well as causing toxicities. months (versus 20% ORR and 8.3

article thumbnail

Bristol Myers Squibb Highlights Targeted Protein Degradation Data, Including CELMoD Agents, at EHA 2025

The Pharma Data

Evidence of Clinical Benefit from CELMoD Agents in Multiple Myeloma The data presented at EHA 2025 further illuminate the potential for CELMoD agents to make a measurable improvement in the lives of patients battling multiple myeloma — a plasma cell malignancy that often relapses after standard treatments and is challenging to control.

article thumbnail

Novel Bispecific therapies in oncology

SugarCone Biotech

The critical question then becomes one of clinical translation finding tumor types that are EGFR-positive and are believed to be immunosuppressed by TGF-. Bicara has focused ficerafusp alfa clinical development on head and neck squamous cell carcinoma (HNSCC), adding pembrolizumab to separately block the PD-1 pathway.

article thumbnail

Novartis Acquires Regulus Therapeutics, Expanding its RNA-Based Drug Pipeline

The Pharma Data

Novartis Finalizes Acquisition of Regulus Therapeutics, Strengthening Its Renal Disease Portfolio with Promising ADPKD Therapy Novartis AG, a leading global pharmaceutical company, has officially completed its acquisition of Regulus Therapeutics Inc. , a biotechnology firm known for its expertise in microRNA-targeting therapies.

RNA 52